I asked the same question a year ago and someone mentioned that Simon said 2mg/kg was still on the table, although there's been nothing in writing, so I would go by the official messaging and assume that it's only one of the doses from stage 1. I'm also not sure if we get a readout for stage 1 002 since that would involve unblinding the study. I'm also not sure how the DMC are evaluating overwhelming/underwhelming efficacy, so I can't read too much into us being allowed to continue the trial without modification. However, if we do get a readout and all doses are underwhelming PAR should be able to reapply to the FDA and request to dose at 2mg/kg.
On another note, today's announcement indicates that we've enrolled 468 patients into PARA 002 in ~ 18 months. So if all goes well, imagine where PAR will be in the next 18 months.
My views, dyor
- Forums
- ASX - By Stock
- PAR
- Ann: PAR Reports Phase 3 Clinical Trial Update
Ann: PAR Reports Phase 3 Clinical Trial Update, page-17
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M |
Open | High | Low | Value | Volume |
22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 99346 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 131244 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 99346 | 0.225 |
5 | 44676 | 0.220 |
7 | 82313 | 0.215 |
13 | 181424 | 0.210 |
8 | 128042 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 131244 | 5 |
0.245 | 56918 | 2 |
0.250 | 89857 | 4 |
0.255 | 100000 | 1 |
0.260 | 1333 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |